U.S. Markets closed

Aravive Inc (ARAV) Files 10-K for the Fiscal Year Ended on December 31, 2018

- By insider

Aravive Inc (ARAV) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Versartis Inc is an endocrine-focused biopharmaceutical company initially developing long-acting recombinant human growth hormone for the treatment of growth hormone deficiency. Aravive Inc has a market cap of $67.875 million; its shares were traded at around $6.07 with and P/S ratio of 0.92.


For the last quarter Aravive Inc reported a revenue of $1.37 million, compared with the revenue of $40.00 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $1.37 million, a decrease of 96.6% from the previous year. For the last five years Aravive Inc had an average revenue decline of 0% a year.

The reported loss per diluted share was $10.64 for the year, compared with the loss per share of $26.34 in the previous year. The Aravive Inc had an operating margin of -5500.51%, compared with the operating margin of -211.21% a year before. The 10-year historical median operating margin of Aravive Inc is -211.21%. The profitability rank of the company is 3 (out of 10).

At the end of the fiscal year, Aravive Inc has the cash and cash equivalents of $57.0 million, compared with $81.1 million in the previous year. The long term debt was $7.32 million, compared with $5.43 million in the previous year. Aravive Inc has a financial strength rank of 5 (out of 10).

At the current stock price of $6.07, Aravive Inc is traded at 37% discount to its historical median P/S valuation band of $9.63. The P/S ratio of the stock is 0.92, while the historical median P/S ratio is 1.40. The stock lost 42.19% during the past 12 months.

For the complete 20-year historical financial data of ARAV, click here.

This article first appeared on GuruFocus.